Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809227 | 0.85 | NR3C1 (0.48) | NR3C1SIGMAR1 | |
| SCHEMBL15673547 | 0.85 | NR3C1 (0.44) | NR3C1SIGMAR1 | |
| SCHEMBL6689892 | 0.82 | NR3C1 (0.43) | NR3C1SIGMAR1 | |
| SCHEMBL5138499 | 0.81 | KDM1A (0.50) | NR3C1SIGMAR1 | |
| SCHEMBL6686815 | 0.79 | NR3C1 (0.41) | NR3C1 | |
| SCHEMBL6688420 | 0.78 | HDAC9 (0.41) | NR3C1SIGMAR1 | |
| SCHEMBL3427758 | 0.76 | NR3C1 (0.40) | NR3C1SIGMAR1 | |
| SCHEMBL808960 | 0.76 | NR3C1 (0.55) | NR3C1 | |
| SCHEMBL809039 | 0.75 | NR3C1 (0.67) | NR3C1 | |
| SCHEMBL23385700 | 0.75 | KDM1A (0.49) | NR3C1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776119-B9 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| EP-1776119-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-7902224-B2 | Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1776119-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006015870-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224130-A1 | Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators | NR3C1, NR3C2, MC2R | NR3C1 1/4885SIGMAR1 545/4885PPARG 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.